Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL

Charalambos (Babis) Andreadis, MD, MSCE
Published: Thursday, Jan 17, 2019



Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

There are 2 approved products now––tisagenlecleucel (Kymriah), which is a 4-IBB product and axicabtagene-ciloleucel (Axi-cel; Yescarta), which is a CD28 product. They have very similar activity, says Andreadis. To date, clinical trials have shown response rates in the 50% range and long-term responses in 30% to 40% of patients, adds Andreadis.

However, they have different toxicity profiles. The toxicity with tisagenlecleucel is mainly low-grade cytokine release syndrome (CRS). There is a little bit of neurological toxicity, though it does not often require secondary agent support. Axi-cel has more of a robust and early onset toxicity profile, says Andreadis. Physicians have noted higher rates of CRS and neurotoxicity, as well as higher use of tocilizumab and steroids, which may make it more challenging to give in the outpatient setting.
SELECTED
LANGUAGE


Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

There are 2 approved products now––tisagenlecleucel (Kymriah), which is a 4-IBB product and axicabtagene-ciloleucel (Axi-cel; Yescarta), which is a CD28 product. They have very similar activity, says Andreadis. To date, clinical trials have shown response rates in the 50% range and long-term responses in 30% to 40% of patients, adds Andreadis.

However, they have different toxicity profiles. The toxicity with tisagenlecleucel is mainly low-grade cytokine release syndrome (CRS). There is a little bit of neurological toxicity, though it does not often require secondary agent support. Axi-cel has more of a robust and early onset toxicity profile, says Andreadis. Physicians have noted higher rates of CRS and neurotoxicity, as well as higher use of tocilizumab and steroids, which may make it more challenging to give in the outpatient setting.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x